Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background/Aims: Serum YKL-40 has been linked to several human cancers. We investigated the potential role of serum YKL-40 as a marker of hepatobiliary malignancies. Methods: Archived serum samples of patients undergoing liver transplantation evaluation at the Mayo Clinic Rochester were used to measure YKL-40 levels. Patients were divided into three groups:hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and end-stage liver disease (ESLD) without malignancies. The Model for ESLD (MELD) score was used to quantify the severity of liver disease. Results: The median serum YKL-40 level was highest in the ESLD group at 296 ng/mL, compared to 259ng/mL in the HCC group and 80 ng/mL in the CCA group (p＜0.01). There was a significant correlation between the MELD score and serum YKL-40 level (r=0.50, p＜0.01). In a multivariate analysis, there was no significant difference in serum YKL-40 level between ESLD and HCC. CCA was associated with lower YKL-40 levels, a finding that was attributable to a lower prevalence of cirrhosis. Conclusions: The serum YKL-40 level has little utility as a cross-sectional screening tool for hepatobiliary malignancies, namely HCC and CCA. The role of YKL-40 as a surveillance marker in the follow-up of individual patients remains to be determined.
Abstract
Background/Aims: Serum YKL-40 has been linked to several human cancers. We investigated the potential role of serum YKL-40 as a marker of hepatobiliary malignancies. Methods: Archived serum samples of patients undergoing liver transplantation evaluation at the Mayo Clinic Rochester were used to measure YKL-40 levels. Patients were divided into three groups:hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and end-stage liver disease (ESLD) without malignancies. The Model for ESLD (MELD) score was used to quantify the severity of liver disease. Results: The median serum YKL-40 level was highest in the ESLD group at 296 ng/mL, compared to 259ng/mL in the HCC group and 80 ng/mL in the CCA group (p＜0.01). There was a significant correlation between the MELD score and serum YKL-40 level (r=0.50, p＜0.01). In a multivariate analysis, there was no significant difference in serum YKL-40 level between ESLD and HCC. CCA was associated with lower YKL-40 levels, a finding that was attributable to a lower prevalence of cirrhosis. Conclusions: The serum YKL-40 level has little utility as a cross-sectional screening tool for hepatobiliary malignancies, namely HCC and CCA. The role of YKL-40 as a surveillance marker in the follow-up of individual patients remains to be determined.
참고문헌 (31)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Johansen JS, "Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer", Dan Med Bull, 53, pp.172~209 (2006)
- Michelsen AE, "Increased YKL-40 expression in patients with carotid atherosclerosis", Atherosclerosis, 211, pp.589~595 (2010)
- Zheng JL, "Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease", Atherosclerosis, 210, pp.590~595 (2010)
- Rathcke CN, "YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria", Diabetes Care, 32, pp.323~328 (2009)
- Nielsen AR, "Plasma YKL-40: a BMI-independent marker of type 2 diabetes", Diabetes, 57, pp.3078~3082 (2008)
- Letuve S, "YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages", J Immunol, 181, pp.5167~5173 (2008)
- Chupp GL, "A chitinase-like protein in the lung and circulation of patients with severe asthma", N Engl J Med, 357, pp.2016~2027 (2007)
- Erzin Y, "Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease", J Gastroenterol Hepatol, 23, pp.e357~e362 (2008)
- Huang K, "YKL-40: a potential biomarker for osteoarthritis", J Int Med Res, 37, pp.18~24 (2009)
- Bi J, "Overexpression of YKL-40 is an independent prognostic marker in gastric cancer", Hum Pathol, 40, pp.1790~1797 (2009)
- Shao R, "YKL-40, a secreted glycoprotein, promotes tumor angiogenesis", Oncogene, 28, pp.4456~4468 (2009)
- Lau SH, "Cytogenetic and molecular genetic alterations in hepatocellular carcinoma", Acta Pharmacol Sin, 26, pp.659~665 (2005)
- Mehta P, "Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C", Am J Gastroenterol, 103, pp.928~936 (2008)
- Johansen JS, "Serum YKL-40 is increased in patients with hepatic fibrosis", J Hepatol, 32, pp.911~920 (2000)
- Saitou Y, "Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease", World J Gastroenterol, 11, pp.476~481 (2005)
- Nojgaard C, "Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease", J Hepatol, 39, pp.179~186 (2003)
- Lee KG, "Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B", J Gastroenterol Hepatol, 25, pp.94~100 (2010)
- Cintin C, "Serum YKL-40 and colorectal cancer", Br J Cancer, 79, pp.1494~1499 (1999)
- Johansen JS, "High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival", Breast Cancer Res Treat, 80, pp.15~21 (2003)
- Johansen JS, "High serum YKL-40 level in patients with small cell lung cancer is related to early death", Lung Cancer, 46, pp.333~340 (2004)
- Roslind A, "High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival", Int J Cancer, 122, pp.857~863 (2008)
- Brasso K, "Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma", Prostate, 66, pp.503~513 (2006)
- Dehn H, "Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer", Acta Obstet Gynecol Scand, 82, pp.287~293 (2003)
- Schmidt H, "Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma", Cancer, 106, pp.1130~1139 (2006)
- Johansen JS, "Is YKL-40 a new therapeutic target in cancer?", Expert Opin Ther Targets, 11, pp.219~234 (2007)
- Johansen JS, "Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population", J Clin Oncol, 27, pp.572~578 (2009)
- Tanwar MK, "Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma", Cancer Res, 62, pp.4364~4368 (2002)
- Lau SH, "Clusterin plays an important role in hepatocellular carcinoma metastasis", Oncogene, 25, pp.1242~1250 (2006)
- Franceschi C, "Inflamm-aging. An evolutionary perspective on immunosenescence", Ann N Y Acad Sci, 908, pp.244~254 (2000)
- Johansen JS, "High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality", Clin Exp Immunol, 151, pp.260~266 (2008)